Compare Quest Diagnostics Inc (DGX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Yum China Holdings Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Yum China Holdings Inc trades at $47.4 (market cap $16.28B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Yum China Holdings Inc pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| DGX | YUMC | |
|---|---|---|
Market Cap | $26.21B | $16.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $57.95 |
52-Week Low | $173.49 | $40.18 |
Enterprise Value | $31.97B | $17.19B |
Dividend Yield | 1.45% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
YUMC trades at $47.92, down 0.56% on the day, with a bullish technical signal supported by moving averages. The company demonstrates consistent fundamental strength with Q2 2026 earnings beating estimates, revenue growth of 13% year-over-year, and a net income margin of 7.84%. Recent completion of the Pizza Hut China acquisition for $1.2 billion positions the company for strategic growth and cost synergies.
The outlook remains positive with strong analyst support (73.68% buy ratings) and a 26.21% upside potential. Key risks include Chinese macroeconomic headwinds and integration challenges from the Pizza Hut acquisition. Earnings momentum and valuation metrics suggest continued growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
